Respiratory Fluoroquinolones: Differences in the Details
نویسندگان
چکیده
منابع مشابه
Newer fluoroquinolones and the management of respiratory tract infections.
Infections of the respiratory tract remain one of the leading causes of death in the United States [1]. The cost burden for bacterial infections of the upper and lower respiratory tract is tremendous; the cost alone of treating patients with communityacquired pneumonia (CAP) has recently been estimated to be close to $10 billion (US) [2]. In addition, the emergence of drugresistant pathogens pr...
متن کاملIn vitro activity of fluoroquinolones against common respiratory pathogens.
The treatment of respiratory infections is often empiric, necessitating the use of agents with a broad range of antimicrobial activity. The fluoroquinolones, having activity against common respiratory pathogens, fit this description. New fluoroquinolones have been developed in an attempt to improve the in vitro activity against a wide variety of respiratory tract pathogens. The objective of the...
متن کاملRole of newer fluoroquinolones in lower respiratory tract infections.
709 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ....
متن کاملTreatment of respiratory tract infections with fluoroquinolones in Belgium
Belgian data on the treatment of respiratory tract infections with antibiotics in ambulatory care showed that fluoroquinolone use remains well controlled. Belgian guidelines have recommended moxifloxacin for CAP outpatients with comorbid conditions or outpatients in whom infection with atypical pathogens needs to be considered. Moxifloxacin is recommended in case of IgE-mediated ß-lactam allerg...
متن کاملNewer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?
Possible masking of tuberculosis (TB) in treatment of community-acquired respiratory infection by newer fluoroquinolones has not been examined in randomised controlled trials. We undertook a randomised, open-label controlled trial involving adults with community-acquired pneumonia or infective exacerbation of bronchiectasis encountered in government chest clinics in Hong Kong. 427 participants ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Infectious Diseases
سال: 2004
ISSN: 1058-4838,1537-6591
DOI: 10.1086/383153